IMMUNIC IMUX 深 沪
交易中 06-25 12:11:57 美东时间
15.09
+0.380
+2.58%
华盛通- 最 高15.37
- 今 开14.81
- 成交量 6.06万股
- 最 低 14.45
- 昨 收 14.71
- 总市值 2.06亿
- 52周最高 15.77
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 5.062
- 委 比 0.00%
- 总股本 1362.15万
- 历史最高 289.90
- 量 比 0.71
- 振 幅 6.25%
- 历史最低 5.062
- 每 手 1
- 风险率 2.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat
Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat Immunic will join the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16 in New York, with a virtual component. Management will take part in BIO International Convention 2026 partnering meetings in Sa
06-10 18:30
EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
Immunic (IMUX) stock rises premarket to $13.14 as the company names former Genentech executive Erik Lundgren as CEO. See how his historic multiple sclerosis drug launch experience accelerates Immunic's Phase 3 trials in 2026.
05-27 18:17
B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27
B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.
05-22 22:16
Immunic Appoints Michael W. Bonney As Board Chairman
Mr. Bonney brings more than three decades of leadership experience in the biopharmaceutical industry, including significant expertise in multiple sclerosis (MS) and broader central nervous system markets. Notably, during
05-19 18:32
Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec
Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec Immunic appointed Michael W. Bonney as chair of the board, effective May 16, 2026. Simona Skerjanec moved from interim chair to remain a board member. Bonney previously held senior commercial leadership roles at Bioge
05-19 18:30
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Immunic Q1 net loss widens on higher R&D spends
Immunic Q1 net loss widens on higher R&D spends Overview US biotechnology firm's Q1 net loss widened to $32.6 mln, or $1.08 per share Company raised $200 mln in private placement, boosting cash to $186.6 mln Outlook Immunic expects to fund operations into late 2027 with current cash position Result
05-13 18:42
Immunic Q1 EPS $(1.08) Misses $(0.91) Estimate
Immunic (NASDAQ:IMUX) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.68 percent. This is a 332 percent decrease over losses of $(0.25) per share from the same
05-13 18:34
Immunic Q1 FY26 net loss widens to $32.6 million
Immunic Q1 FY26 net loss widens to $32.6 million Immunic posted a net loss of USD 32.6 million for first-quarter 2026, widening from a loss of USD 25.5 million a year earlier. Loss per share narrowed to USD 1.08 from USD 2.51, while R&D expense climbed 19.07% to USD 25.6 million and G&A costs rose 4
05-13 18:30
美股机会日报 | 太意外！美官员突然宣布：敌对行动已结束；五角大楼与谷歌、英伟达、SpaceX等签署协议！
太意外！美官员突然宣布：敌对行动已结束；五角大楼：已与SpaceX、谷歌和英伟达签署协议！获批合法军事作战用途；苹果盘前涨近4%，营收指引意外强劲>>
05-01 20:09
